2. Protein Tyrosine Kinase/RTK Autophagy Apoptosis
  3. Bcr-Abl Src Autophagy Apoptosis
  4. Dasatinib monohydrate

Dasatinib monohydrate  (Synonyms: BMS-354825 monohydrate)

Cat. No.: HY-10181B Purity: 99.58%
COA
SDS
Handling Instructions Technical Support

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib monohydrate also induces apoptosis and autophagy.

For research use only. We do not sell to patients.

CAS No. : 863127-77-9

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 168 publication(s) in Google Scholar

Other Forms of Dasatinib monohydrate:

Dasatinib monohydrate Related Antibodies

Top Publications Citing Use of Products

168 Publications Citing Use of MCE Dasatinib monohydrate

Cell Proliferation/Viability Assay
In Vivo Efficacy Study
WB
ELISA
IF
Cell Migration/Invasion Assay
RT-PCR
Cell Imaging/Staining

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545.  [Abstract]

    Dasatinib (100 nM; 24 h). mRNA relative expression of CDKN2A, IL-6 and IL-8 in si-FOXP1 COV434 treated with fisetin (F), quercetin (Q) and Dasatinib (D).

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545.  [Abstract]

    Dasatinib (100 nM; 24 h). Immunofluorescence staining of Ki67 upon administration of fisetin (F), quercetin (Q) and Dasatinib (D) in COV434 with knockdown of FOXP1.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545.  [Abstract]

    Dasatinib (100 nM; 24 h). Immunofluorescence staining of γH2AX upon administration of fisetin (F), quercetin (Q) and dasatinib (D) in COV434 with knockdown of FOXP1.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545.  [Abstract]

    Fisetin (10 μM, 24 h), Quercetin (10 μM, 24 h), or Dasatinib (100 nM, 24 h) delayed FOXP1 gene silencing-induced cellular senescence in COV434 cells.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Mar;25(3):493-507.  [Abstract]

    Dasatinib (50 nM; 24 or 48 h) significantly decreases MED8A and D458 cell migration.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Mar;25(3):493-507.  [Abstract]

    Dasatinib (50 nM;24 h-48 h) significantly decreases MED8A cell migration.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2023 Aug 29:14:1250383.  [Abstract]

    Dasatinib hydrochloride (Dasatinib; 20 μM; 2 h) suppressed silica particle (SP)-induced cell death. Bone marrow-derived macrophages (BMDMs) were primed with lipopolysaccharide (LPS) (200 ng/mL) for 6 h. The cells were then treated with 20 µM of bosutinib, dasatinib, PD-161570, or PD-166285 and were stimulated or not stimulated with SPs (1,500 nm in diameter, 300 μg/mL) for 2 h. The cell death rate was determined by measuring lactate dehydrogenase (LDH) activity in the culture supernatant.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109.  [Abstract]

    YSE450-R and EC109-R cells are treated with 200 nM BIBW 2992 alone or in combination with 100 nM Dasatinib for 48 h.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109.  [Abstract]

    Resistant cells were treated with the indicated concentrations of afatinib in the presence or absence of 100 nM Dasatinib hydrochloride (Dasatinib) for 72 h, and CCK-8 assays were performed to assess cell viability.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109.  [Abstract]

    Dasatinib hydrochloride (dasatinib; 15 mg/kg; daily for 21 days) showed anti-cancer activity in the xenograft growth of KYSE450-R and PDX03-R mice.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109.  [Abstract]

    Dasatinib hydrochloride (dasatinib; 15 mg/kg; daily for 21 days) decreased the expression of phosphorylated S6 and ERK after afatinib combined with dasatinib treatment in xenografts growth of KYSE450-R and PDX03-R mice.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109.  [Abstract]

    Dasatinib hydrochloride (Dasatinib; 20 μM; 2 h) suppressed silica particle (SP)-induced IL-1α and IL-1β release in BMDMs. Bone marrow-derived macrophages (BMDMs) were primed with lipopolysaccharide (LPS) (200 ng/mL) for 6 h. The cells were then treated with 20 µM of bosutinib, dasatinib, PD-161570, or PD-166285 and were stimulated or not stimulated with SPs (1,500 nm in diameter, 300 μg/mL) for 2 h. IL-1α and IL-1 beta (β) levels in the culture supernatants were measured using enzyme-linked immunosorbent assay (ELISA).

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109.  [Abstract]

    Dasatinib hydrochloride (Dasatinib; 20 μM; 4 h) suppressed SP-induced cell death accompanied by IL-1α and IL-1β release in phorbol 12-myristate 13-acetatetreated macrophage-like THP-1 cells. Phorbol 12-myristate 13-acetate-differentiated THP-1 cells were primed with LPS (50 ng/mL) for 16 h. The cells were then treated with dasatinib (20 µM) and were stimulated or not stimulated with SPs (1,500 nm in diameter, 500 μg/mL) for 4 h.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109.  [Abstract]

    Dasatinib hydrochloride (Dasatinib; 20 μM; 2 h) suppressed silica particle (SP)-induced cell death. Bone marrow-derived macrophages (BMDMs) were primed with lipopolysaccharide (LPS) (200 ng/mL) for 6 h. The cells were then treated with 20 µM of bosutinib, dasatinib, PD-161570, or PD-166285 and were stimulated or not stimulated with SPs (1,500 nm in diameter, 300 μg/mL) for 2 h. The cell death rate was determined by measuring lactate dehydrogenase (LDH) activity in the culture supernatant.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Biol Pharm Bull. 2017;40(10):1747-1753.  [Abstract]

    Synergistic Decrease Bcl-2 Expression by the Combination of SAHA with Dasatinib in MCF-7 Cells.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Chem Pharm Bull (Tokyo). 2017 Aug 1;65(8):768-775.  [Abstract]

    Changes in Bcl-2 protein expression in MCF-7 cells after treatment with NSC 105014, Dasatinib or ZD1839 alone or in combination for 12 h. Expression of Bcl-2 protein is analyzed by western blotting analysis.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Kawasaki Medical Journal. 43(2)：63-78，2017.

    Western blot analysis of effects of Dasatinib (10 or 100nM) on c-Src, p-SrcY416, FAK and p-FAKY861 expression levels in KTC-1 cells and band intensities for p-SrcY416.

    Dasatinib monohydrate purchased from MedChemExpress. Usage Cited in: Leukemia. 2012 Oct;26(10):2233-44.  [Abstract]

    Drug combination effect on phosphorylation of AKT. Expression of phospho-AKT and total AKT in MOLM13 cells treated for 15 minutes with DMSO vehicle, PKC412 (2.5 nM), Dasatinib (165 nM), or a combination of both. Protein lysates are prepared from MOLM13 cells, and are analyzed via immunoblotting with antibodies to phospho-AKT and total AKT.

    View All Bcr-Abl Isoform Specific Products:

    View All Isoforms
    Abl Bcr-Abl

    View All Src Isoform Specific Products:

    View All Isoforms
    Lck Fyn Blk Fgr Hck Lyn Yes SRC-3

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib monohydrate also induces apoptosis and autophagy.

    IC50 & Target[1]

    Bcr-Abl

    1.0 nM (IC50)

    Src

    0.5 nM (IC50)

    lck

    0.4 nM (IC50)

    yes

    0.5 nM (IC50)

    c-kit

    5.0 nM (IC50)

    PDGFRβ

    28 nM (IC50)

    p38

    100 nM (IC50)

    Her1

    180 nM (IC50)

    Her2

    710 nM (IC50)

    FGFR-1

    880 nM (IC50)

    MEK

    1700 nM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    A2780 IC50
    8.7 μM
    Compound: 1, Dasatinib
    Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
    		[PMID: 25815152]
    A549 IC50
    12.66 μM
    Compound: 3
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    A549 IC50
    23.73 μM
    Compound: Dasatinib
    Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 30562697]
    A549 IC50
    8.2 μM
    Compound: Dasatinib, BMS-354825
    Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay
    Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay
    		[PMID: 23567960]
    A549 IC50
    8.37 μM
    Compound: Dasatinib
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 27155464]
    BXPC-3 EC50
    33 nM
    Compound: Dasatinib
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    BaF3 EC50
    0.04 nM
    Compound: Dasatinib
    Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 27010810]
    BaF3 EC50
    > 10 μM
    Compound: Dasatinib
    Antiproliferative activity against wild type mouse BA/F3 cells incubated for 3 days by CCK8 assay
    Antiproliferative activity against wild type mouse BA/F3 cells incubated for 3 days by CCK8 assay
    		[PMID: 32657579]
    BaF3 EC50
    > 10 μM
    Compound: Dasatinib
    Protac activity at Cereblon/BCR/ABL T315I mutant (unknown origin) expressed in mouse BaF3 cells assessed as reduction in BCR-ABL T315I mutant driven cell viability incubated for 3 days by CCK8 assay
    Protac activity at Cereblon/BCR/ABL T315I mutant (unknown origin) expressed in mouse BaF3 cells assessed as reduction in BCR-ABL T315I mutant driven cell viability incubated for 3 days by CCK8 assay
    		[PMID: 32657579]
    BaF3 EC50
    > 1000 nM
    Compound: Dasatinib
    Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 27010810]
    BaF3 GI50
    0.001 μM
    Compound: Dasatinib
    Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.001 μM
    Compound: Dasatinib
    Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.003 μM
    Compound: Dasatinib
    Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.003 μM
    Compound: Dasatinib
    Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.004 μM
    Compound: Dasatinib
    Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.005 μM
    Compound: Dasatinib
    Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.008 μM
    Compound: Dasatinib
    Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.01 μM
    Compound: Dasatinib
    Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.014 μM
    Compound: Dasatinib
    Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.017 μM
    Compound: Dasatinib
    Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.039 μM
    Compound: Dasatinib
    Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    3 μM
    Compound: Dasatinib
    Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    3 μM
    Compound: Dasatinib
    Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    9.94 μM
    Compound: Dasatinib
    Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    < 0.0003 μM
    Compound: Dasatinib
    Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    > 10 μM
    Compound: Dasatinib
    Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    0.0002 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.0009 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.0013 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.0019 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.0023 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.0032 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.0051 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.008 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.015 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.017 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.019 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.023 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.025 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.029 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.09 μM
    Compound: Dasatinib
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay
    		[PMID: 26814890]
    BaF3 IC50
    0.12 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    0.31 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    0.51 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    0.58 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    0.58 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    0.7 nM
    Compound: Dasatinib
    Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    BaF3 IC50
    0.83 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    1.29 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    1.71 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    1.72 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    1.91 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    1.94 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    1714 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    2.5 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    3.6 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    3.8 μM
    Compound: 3
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    4.5 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    5.72 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    6.55 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    6589 nM
    Compound: 3, BMS-354825
    Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    > 1 μM
    Compound: Dasatinib
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    		[PMID: 26195136]
    BaF3 IC50
    > 100 nM
    Compound: Dasatinib
    Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay
    Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay
    		[PMID: 34011155]
    CAKI-2 EC50
    55 nM
    Compound: Dasatinib
    Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    CHO IC50
    81.1 μM
    Compound: dasatinib
    Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
    Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
    		[PMID: 23812503]
    DLD-1 IC50
    4.6 μM
    Compound: Dasatinib, BMS-354825
    Cytotoxicity against human DLD1 cells after 72 hrs by WST-8 assay
    Cytotoxicity against human DLD1 cells after 72 hrs by WST-8 assay
    		[PMID: 23567960]
    DU-145 GI50
    0.0623 μM
    Compound: Dasatinib
    Antiproliferative activity against human PRXF DU145 cells after 4 days by modified propidium iodide assay
    Antiproliferative activity against human PRXF DU145 cells after 4 days by modified propidium iodide assay
    		[PMID: 25076195]
    DU-145 GI50
    0.16 μM
    Compound: Sprycel, NSC 723517
    Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
    		[PMID: 24015327]
    DU-145 IC50
    0.0623 μM
    Compound: Dasatinib
    Cytotoxicity against human PRXF DU145 cells after 4 days by propidium iodide staining
    Cytotoxicity against human PRXF DU145 cells after 4 days by propidium iodide staining
    		[PMID: 23253074]
    DU-145 IC50
    2.43 μM
    Compound: 93
    Cytotoxicity against human DU-145 cells
    Cytotoxicity against human DU-145 cells
    		[PMID: 33077264]
    Daoy GI50
    2927 nM
    Compound: Dasatinib
    Antiproliferative activity against human DaOY cells
    Antiproliferative activity against human DaOY cells
    		[PMID: 29617135]
    HCT-116 GI50
    3.7 μM
    Compound: Sprycel, NSC 723517
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
    		[PMID: 24015327]
    HCT-116 GI50
    880 nM
    Compound: Dasatinib
    Antiproliferative activity against human HCT116 cells
    Antiproliferative activity against human HCT116 cells
    		[PMID: 29617135]
    HCT-116 IC50
    2.3 μM
    Compound: 3
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    HCT-116 IC50
    3.58 μM
    Compound: Dasatinib
    Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 30562697]
    HCT-116 IC50
    5.23 μM
    Compound: Dasatinib
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 27155464]
    HCT-116 IC50
    5.3 μM
    Compound: Dasatinib, BMS-354825
    Cytotoxicity against human HCT116 cells after 72 hrs by WST-8 assay
    Cytotoxicity against human HCT116 cells after 72 hrs by WST-8 assay
    		[PMID: 23567960]
    HEK293 CC50
    16 μM
    Compound: Dasatinib
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability
    		[PMID: 26264503]
    HEK293 EC50
    0.47 μM
    Compound: Dasatinib
    Inhibition of recombinant Nanoluc-tagged p38alpha (unknown origin) expressed in HEK293 cells incubated for 2 to 3 mins by NanoBRET assay
    Inhibition of recombinant Nanoluc-tagged p38alpha (unknown origin) expressed in HEK293 cells incubated for 2 to 3 mins by NanoBRET assay
    		[PMID: 31520926]
    HEK293 IC50
    14.3 μM
    Compound: 1, Dasatinib
    Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
    		[PMID: 25815152]
    HEK293 IC50
    63 nM
    Compound: Dasatinib
    Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells by TR-FRET based binding assay
    Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells by TR-FRET based binding assay
    		[PMID: 22770610]
    HEL GI50
    5.3 μM
    Compound: Dasatinib
    Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    HL-60 IC50
    0.11 nM
    Compound: Dasatinib
    Growth inhibition of human HL60 cells
    Growth inhibition of human HL60 cells
    		[PMID: 29395973]
    HL-60 IC50
    14.97 μM
    Compound: Dasatinib
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    		[PMID: 36242991]
    HMEC GI50
    1.8 μM
    Compound: Sprycel, NSC 723517
    Cytotoxicity against human HMEC after 72 hrs by WST1 assay
    Cytotoxicity against human HMEC after 72 hrs by WST1 assay
    		[PMID: 24015327]
    HepG2 IC50
    7.5 μM
    Compound: Dasatinib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 27739679]
    HepG2 IC50
    > 5 μM
    Compound: dasatinib
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 25835317]
    Hs-578T GI50
    0.03 μM
    Compound: Sprycel, NSC 723517
    Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay
    Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay
    		[PMID: 24015327]
    JeKo-1 IC50
    1325 nM
    Compound: Dasatinib
    Growth inhibition of human Jeko-1 cells incubated for 72 hrs
    Growth inhibition of human Jeko-1 cells incubated for 72 hrs
    		[PMID: 33479666]
    Jurkat GI50
    8 nM
    Compound: Dasatinib
    Antiproliferative activity against human Jurkat cells
    Antiproliferative activity against human Jurkat cells
    		[PMID: 29617135]
    Jurkat IC50
    > 1000 nM
    Compound: Dasatinib
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    K-562R GI50
    0.81 nM
    Compound: Dasatinib
    Antiproliferative activity against human K562R cells
    Antiproliferative activity against human K562R cells
    		[PMID: 29617135]
    K562 CC50
    0.25 μM
    Compound: VI
    Cytotoxicity against human K562 cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against human K562 cells assessed as decrease in cell viability by MTT assay
    		[PMID: 27474918]
    K562 EC50
    0.26 nM
    Compound: Dasatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 3 days in the presence of asciminib by celltiter-glo 2.0 assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 3 days in the presence of asciminib by celltiter-glo 2.0 assay
    		[PMID: 37849551]
    K562 EC50
    0.28 nM
    Compound: Dasatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 3 days by celltiter-glo 2.0 assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 3 days by celltiter-glo 2.0 assay
    		[PMID: 37849551]
    K562 EC50
    11.99 nM
    Compound: Dasatinib
    Antiproliferative activity against human K562 cells expressing ABL T315I mutant assessed as inhibition of cell growth incubated for 3 days in the presence of asciminib by celltiter-glo 2.0 assay
    Antiproliferative activity against human K562 cells expressing ABL T315I mutant assessed as inhibition of cell growth incubated for 3 days in the presence of asciminib by celltiter-glo 2.0 assay
    		[PMID: 37849551]
    K562 GI50
    0.0004 μM
    Compound: BMS-354825
    Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay
    Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay
    		[PMID: 35944901]
    K562 GI50
    0.37 nM
    Compound: Dasatinib
    Antiproliferative activity against human K562 cells
    Antiproliferative activity against human K562 cells
    		[PMID: 29617135]
    K562 GI50
    9.7 μM
    Compound: BMS-354825
    Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay
    Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay
    		[PMID: 35944901]
    K562 GI50
    < 0.0003 μM
    Compound: Dasatinib
    Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    K562 GI50
    < 1 nM
    Compound: Dasatinib
    Antiproliferative activity against human K562 cells
    Antiproliferative activity against human K562 cells
    		[PMID: 28435526]
    K562 IC50
    0.00025 μM
    Compound: Dasatinib
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26814890]
    K562 IC50
    0.00063 μM
    Compound: 3
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability by measuring ATP level incubated for 3 days by Celltiter-Glo assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability by measuring ATP level incubated for 3 days by Celltiter-Glo assay
    		[PMID: 31303996]
    K562 IC50
    0.0007 μM
    Compound: 3
    Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay
    		[PMID: 23521020]
    K562 IC50
    0.001 μM
    Compound: Dasatinib
    Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    		[PMID: 26195136]
    K562 IC50
    0.001 μM
    Compound: Dasatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    		[PMID: 36242991]
    K562 IC50
    0.069 nM
    Compound: Dasatinib
    Growth inhibition of human K562 cells
    Growth inhibition of human K562 cells
    		[PMID: 29395973]
    K562 IC50
    0.08 μM
    Compound: Dasatinib
    Cytotoxicity against human K562 cells assessed as reduction in cell viability
    Cytotoxicity against human K562 cells assessed as reduction in cell viability
    		[PMID: 26264503]
    K562 IC50
    0.19 nM
    Compound: Dasatinib
    Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay
    Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay
    		[PMID: 32657579]
    K562 IC50
    0.2 nM
    Compound: Dasatinib
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    K562 IC50
    0.45 μM
    Compound: BMS-354825
    Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26451772]
    K562 IC50
    0.9 nM
    Compound: Dasatinib
    Growth inhibition of human K562 cells incubated for 2 days by CCK8 assay
    Growth inhibition of human K562 cells incubated for 2 days by CCK8 assay
    		[PMID: 31539241]
    K562 IC50
    0.9 nM
    Compound: Dasatinib
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay
    		[PMID: 34217059]
    K562 IC50
    1 nM
    Compound: 2, dasatinib,BMS-354825
    Growth inhibition of human K562 cells after 48 hrs by [3H]thymidine uptake assay
    Growth inhibition of human K562 cells after 48 hrs by [3H]thymidine uptake assay
    		[PMID: 17956080]
    K562 IC50
    11.9 μM
    Compound: Dasatinib, BMS-354825
    Cytotoxicity against human K562 cells after 72 hrs by WST-8 assay
    Cytotoxicity against human K562 cells after 72 hrs by WST-8 assay
    		[PMID: 23567960]
    K562 IC50
    11.95 μM
    Compound: Dasatinib
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 27155464]
    K562 IC50
    12.83 μM
    Compound: BMS-354825, SPRYCEL
    Cytotoxicity against human K562 cells after 72 hrs by WST-8 reagent based MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by WST-8 reagent based MTT assay
    		[PMID: 22217877]
    K562 IC50
    52 nM
    Compound: Dasatinib Monohydrate
    Antiproliferative activity against human K562 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells incubated for 72 hrs by MTT assay
    		[PMID: 36758304]
    K562 IC50
    7.44 μM
    Compound: 93
    Cytotoxicity against human K562 cells
    Cytotoxicity against human K562 cells
    		[PMID: 33077264]
    K562 IC50
    < 1 nM
    Compound: 13, BMS-354825
    Antiproliferative activity against human K562 cells after 72 hrs
    Antiproliferative activity against human K562 cells after 72 hrs
    		[PMID: 15615512]
    K562 IC50
    < 1 nM
    Compound: Dasatinib Hydrate
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 37801827]
    KG-1a IC50
    8.98 μM
    Compound: Dasatinib
    Growth inhibition of human KG1a cells
    Growth inhibition of human KG1a cells
    		[PMID: 29395973]
    KM12 GI50
    7.44 μM
    Compound: Sprycel, NSC 723517
    Cytotoxicity against human KM12 cells after 48 hrs by SRB assay
    Cytotoxicity against human KM12 cells after 48 hrs by SRB assay
    		[PMID: 24015327]
    L02 IC50
    > 40 μM
    Compound: Dasatinib
    Cytotoxicity against human L02 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 27155464]
    LN-18 GI50
    565 nM
    Compound: Dasatinib
    Antiproliferative activity against human LN18 cells
    Antiproliferative activity against human LN18 cells
    		[PMID: 29617135]
    Leukemia cell IC50
    1 nM
    Compound: Dasatinib
    Antiproliferative activity against human CML cells
    Antiproliferative activity against human CML cells
    		[PMID: 19219016]
    MCF7 GI50
    8.32 μM
    Compound: Sprycel, NSC 723517
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 24015327]
    MCF7 IC50
    1.11 μM
    Compound: Dasatinib
    Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 30562697]
    MCF7 IC50
    2.57 μM
    Compound: 3
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    MCF7 IC50
    8.05 μM
    Compound: 1a
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 25899332]
    MDA-MB-231 EC50
    44 nM
    Compound: Dasatinib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    MDA-MB-231 GI50
    0.02 μM
    Compound: Sprycel, NSC 723517
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 24015327]
    MDA-MB-231 IC50
    0.112 μM
    Compound: Dasatinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 27739679]
    MDA-MB-231 IC50
    0.178 μM
    Compound: dasatinib
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 25835317]
    MDA-MB-231 IC50
    1.12 μM
    Compound: 1a
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 25899332]
    MDA-MB-231 IC50
    12 nM
    Compound: 13, BMS-354825
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs
    		[PMID: 15615512]
    MDA-MB-231 IC50
    12 nM
    Compound: Dasatinib Hydrate
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 37801827]
    MDA-MB-231 IC50
    12 nM
    Compound: Dasatinib Monohydrate
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
    		[PMID: 36758304]
    MDA-MB-435 IC50
    5.147 μM
    Compound: Dasatinib
    Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 27739679]
    MDA-MB-435S IC50
    3.9 μM
    Compound: 3
    Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    MEG-01 GI50
    < 0.0003 μM
    Compound: Dasatinib
    Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    MOLM-14 GI50
    2.3 μM
    Compound: Dasatinib
    Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    MOLT-4 GI50
    644 nM
    Compound: Dasatinib
    Antiproliferative activity against human MOLT4 cells
    Antiproliferative activity against human MOLT4 cells
    		[PMID: 29617135]
    MV4-11 GI50
    3.6 μM
    Compound: Dasatinib
    Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    Malme-3M GI50
    6.61 μM
    Compound: Sprycel, NSC 723517
    Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay
    Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay
    		[PMID: 24015327]
    Maver1 IC50
    1325 nM
    Compound: Dasatinib
    Growth inhibition of human MAVER-1 cells incubated for 72 hrs
    Growth inhibition of human MAVER-1 cells incubated for 72 hrs
    		[PMID: 33479666]
    NCI-H1975 EC50
    173 nM
    Compound: Dasatinib
    Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay
    		[PMID: 27010810]
    NCI-H226 GI50
    163 nM
    Compound: Dasatinib
    Antiproliferative activity against human NCI-H226 cells
    Antiproliferative activity against human NCI-H226 cells
    		[PMID: 29617135]
    NCI-H2286 IC50
    0.032 μM
    Compound: Dasatinib
    Antiproliferative activity against human NCI-H2286 cells expressing DDR2 mutant after 72 hrs by alamar blue assay
    Antiproliferative activity against human NCI-H2286 cells expressing DDR2 mutant after 72 hrs by alamar blue assay
    		[PMID: 26191369]
    NCI-H2286 IC50
    33.3 nM
    Compound: Dasatinib
    Antiproliferative activity against human NCI-H2286 cells harboring DDR2 mutation after 72 hrs by CCK8 assay
    Antiproliferative activity against human NCI-H2286 cells harboring DDR2 mutation after 72 hrs by CCK8 assay
    		[PMID: 30572178]
    NCI-H23 IC50
    2.27 μM
    Compound: 3
    Antiproliferative activity against human NCI-H23 cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H23 cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    NCI-H460 GI50
    90 nM
    Compound: Dasatinib
    Antiproliferative activity against human H460 cells
    Antiproliferative activity against human H460 cells
    		[PMID: 29617135]
    NCI-H460 IC50
    8.99 μM
    Compound: 3
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    NCI-H661 IC50
    7.8 μM
    Compound: Dasatinib, BMS-354825
    Cytotoxicity against human NCI-H661 cells after 72 hrs by WST-8 assay
    Cytotoxicity against human NCI-H661 cells after 72 hrs by WST-8 assay
    		[PMID: 23567960]
    NHDF IC50
    0.71 μM
    Compound: Dasatinib
    Antiproliferative activity against human NHDF cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against human NHDF cells after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 30562697]
    PBMC EC50
    1.6 μM
    Compound: Dasatinib
    Hematotoxicity in human PHA/IL2-stimulated PBMC
    Hematotoxicity in human PHA/IL2-stimulated PBMC
    		[PMID: 27010810]
    PC-3 EC50
    232 nM
    Compound: Dasatinib
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    PC-3 IC50
    9.4 nM
    Compound: 13, BMS-354825
    Antiproliferative activity against human PC3 cells after 72 hrs
    Antiproliferative activity against human PC3 cells after 72 hrs
    		[PMID: 15615512]
    PC-3 IC50
    9.4 nM
    Compound: Dasatinib Hydrate
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 37801827]
    PC-3 IC50
    9.4 nM
    Compound: Dasatinib Monohydrate
    Antiproliferative activity against human PC-3 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells incubated for 72 hrs by MTT assay
    		[PMID: 36758304]
    SK-N-FI GI50
    13 nM
    Compound: Dasatinib
    Antiproliferative activity against human SK-N-FI cells
    Antiproliferative activity against human SK-N-FI cells
    		[PMID: 29617135]
    SK-N-MC GI50
    5114 nM
    Compound: Dasatinib
    Antiproliferative activity against human SK-N-MC cells
    Antiproliferative activity against human SK-N-MC cells
    		[PMID: 29617135]
    SW-620 GI50
    2418 nM
    Compound: Dasatinib
    Antiproliferative activity against human SW620 cells
    Antiproliferative activity against human SW620 cells
    		[PMID: 29617135]
    SW-620 GI50
    8.43 μM
    Compound: Sprycel, NSC 723517
    Cytotoxicity against human SW620 cells after 48 hrs by SRB assay
    Cytotoxicity against human SW620 cells after 48 hrs by SRB assay
    		[PMID: 24015327]
    SW1088 GI50
    898 nM
    Compound: Dasatinib
    Antiproliferative activity against human SW1088 cells
    Antiproliferative activity against human SW1088 cells
    		[PMID: 29617135]
    T-cell IC50
    3 nM
    Compound: 2, BMS-354825
    Inhibition of anti CD3/anti CD28-induced T cell proliferation
    Inhibition of anti CD3/anti CD28-induced T cell proliferation
    		[PMID: 17154512]
    T47D IC50
    0.9 μM
    Compound: 3
    Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
    Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    THP-1 IC50
    6 μM
    Compound: Dasatinib
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability
    		[PMID: 26264503]
    U-251 GI50
    2.81 μM
    Compound: Sprycel, NSC 723517
    Cytotoxicity against human U251 cells after 48 hrs by SRB assay
    Cytotoxicity against human U251 cells after 48 hrs by SRB assay
    		[PMID: 24015327]
    U-87MG ATCC GI50
    1586 nM
    Compound: Dasatinib
    Antiproliferative activity against human U87 cells
    Antiproliferative activity against human U87 cells
    		[PMID: 29617135]
    U-937 GI50
    > 10 μM
    Compound: Dasatinib
    Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    U-937 IC50
    10.23 μM
    Compound: Dasatinib
    Cytotoxicity against human U937 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human U937 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 27155464]
    U-937 IC50
    12.2 μM
    Compound: Dasatinib, BMS-354825
    Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay
    Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay
    		[PMID: 23567960]
    U-937 IC50
    13.63 μM
    Compound: BMS-354825, SPRYCEL
    Cytotoxicity against human U937 cells after 72 hrs by WST-8 reagent based MTT assay
    Cytotoxicity against human U937 cells after 72 hrs by WST-8 reagent based MTT assay
    		[PMID: 22217877]
    U-937 IC50
    15.02 μM
    Compound: Dasatinib
    Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    		[PMID: 36242991]
    U-937 IC50
    > 1000 nM
    Compound: Dasatinib
    Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    U-937 IC50
    >= 100 nM
    Compound: dasatinib
    Inhibition of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells at >= 100 nM after 1 hr
    Inhibition of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells at >= 100 nM after 1 hr
    		[PMID: 17684099]
    Vero C1008 CC50
    > 10 μM
    Compound: 22; BMS-354825
    Cytotoxicity against African green monkey Vero E6 cells
    Cytotoxicity against African green monkey Vero E6 cells
    		[PMID: 33539089]
    WiDr IC50
    52 nM
    Compound: 13, BMS-354825
    Antiproliferative activity against human WiDr cells after 72 hrs
    Antiproliferative activity against human WiDr cells after 72 hrs
    		[PMID: 15615512]
    WiDr IC50
    52 nM
    Compound: Dasatinib Hydrate
    Antiproliferative activity against human WiDr cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human WiDr cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 37801827]
    WiDr IC50
    < 1 nM
    Compound: Dasatinib Monohydrate
    Antiproliferative activity against human WiDr cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human WiDr cells incubated for 72 hrs by MTT assay
    		[PMID: 36758304]
    In Vitro

    Dasatinib demonstrates significant activity against Bcr-Abl, Src, Lck, Yes, c-Kit, PDGFRβ, p38, Her1, Her2, FGFR-1, and MEK with IC50s of <1.0, 0.50, 0.40, 0.50, 5.0, 28, 100, 180, 720, 880, and 1700 nM, respectively[1].
    Dasatinib shows antiproliferative activities aversus K562 chronic myelogenous leukemia (CML), PC3 human prostate tumor, MDA-MB-231 human breast tumor, and WiDr human colon tumor cell lines with IC50s of <1.0 nM, 9.4 nM, 12 nM, and 52 nM, respectively[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Dasatinib monohydrate Related Antibodies
    In Vivo

    Dasatinib (5 mg/kg and 50 mg/kg, qd×10d, 5 on-2 off) possesses potent antitumor activity and a high safety margin in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels[1].
    Dasatinib (10 mg/kg) has a pharmacokinetic profile appropriate for continued advancement into in vivo efficacy studies. Dasatinib (10 mg/kg) demonstrates favorable half-lives (t1/2s) of 3.3 and 3.1 h for i.v. and oral, respectively. The oral bioavailability (Fpo) in this study is 27%[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Nude mice bearing K562 xenografts
    Dosage: 5 mg/kg and 50 mg/kg
    Administration: Oral administration on a 5 day on and 2 day off schedule.
    Result: Showed partial tumor regressions after one treatment cycle and complete disappearance of the tumor mass by the end of drug treatment. No toxicity (animal deaths, lack of weight gain) was observed.
    Animal Model: Sprague-Dawley Rats
    Dosage: 10 mg/kg (Pharmacokinetic Analysis)
    Administration: Oral and i.v.
    Result: Cmax of 13.2 and 0.5 μM for i.v. and oral, respectively.
    Molecular Weight

    506.02

    Formula

    C22H28ClN7O3S
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1)NC4=C(C)C=CC=C4Cl.[H]O[H]
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (197.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9762 mL 9.8810 mL 19.7621 mL
    5 mM 0.3952 mL 1.9762 mL 3.9524 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (4.94 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.9762 mL 9.8810 mL 19.7621 mL 49.4052 mL
    5 mM 0.3952 mL 1.9762 mL 3.9524 mL 9.8810 mL
    10 mM 0.1976 mL 0.9881 mL 1.9762 mL 4.9405 mL
    15 mM 0.1317 mL 0.6587 mL 1.3175 mL 3.2937 mL
    20 mM 0.0988 mL 0.4941 mL 0.9881 mL 2.4703 mL
    25 mM 0.0790 mL 0.3952 mL 0.7905 mL 1.9762 mL
    30 mM 0.0659 mL 0.3294 mL 0.6587 mL 1.6468 mL
    40 mM 0.0494 mL 0.2470 mL 0.4941 mL 1.2351 mL
    50 mM 0.0395 mL 0.1976 mL 0.3952 mL 0.9881 mL
    60 mM 0.0329 mL 0.1647 mL 0.3294 mL 0.8234 mL
    80 mM 0.0247 mL 0.1235 mL 0.2470 mL 0.6176 mL
    100 mM 0.0198 mL 0.0988 mL 0.1976 mL 0.4941 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Dasatinib monohydrate Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Dasatinib863127-77-9BMS-354825BMS354825BMS 354825Bcr-AblSrcAutophagyApoptosisorallyactiveantitumorantiproliferativeK562CMLPC3prostateMDA-MB-231breastWiDrcolonInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Dasatinib monohydrate
    Cat. No.:
    HY-10181B
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.